🎉 M&A multiples are live!
Check it out!

Syngene International Valuation Multiples

Discover revenue and EBITDA valuation multiples for Syngene International and similar public comparables like Cohance Lifesciences, Dishman Carbogen Amics, and Piramal Pharma.

Syngene International Overview

About Syngene International

Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The Company is engaged in a single operating segment of providing contract research and manufacturing services. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the US. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.


Founded

1993

HQ

India
Employees

8.2K+

Website

syngeneintl.com

Financials

LTM Revenue $436M

LTM EBITDA $121M

EV

$3.0B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 12K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Syngene International Financials

Syngene International has a last 12-month revenue (LTM) of $436M and a last 12-month EBITDA of $121M.

In the most recent fiscal year, Syngene International achieved revenue of $411M and an EBITDA of $134M.

Syngene International expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Syngene International valuation multiples based on analyst estimates

Syngene International P&L

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue $436M XXX $411M XXX XXX XXX
Gross Profit $322M XXX $301M XXX XXX XXX
Gross Margin 74% XXX 73% XXX XXX XXX
EBITDA $121M XXX $134M XXX XXX XXX
EBITDA Margin 28% XXX 33% XXX XXX XXX
EBIT $71.3M XXX $71.8M XXX XXX XXX
EBIT Margin 16% XXX 17% XXX XXX XXX
Net Profit $54.6M XXX $58.0M XXX XXX XXX
Net Margin 13% XXX 14% XXX XXX XXX
Net Debt XXX XXX n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Syngene International Stock Performance

As of July 16, 2025, Syngene International's stock price is INR 655 (or $8).

Syngene International has current market cap of INR 263B (or $3.1B), and EV of INR 255B (or $3.0B).

See Syngene International trading valuation data

Syngene International Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$3.0B $3.1B XXX XXX XXX XXX $0.13

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Syngene International Valuation Multiples

As of July 16, 2025, Syngene International has market cap of $3.1B and EV of $3.0B.

Syngene International's trades at 7.3x EV/Revenue multiple, and 22.6x EV/EBITDA.

Equity research analysts estimate Syngene International's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

Syngene International has a P/E ratio of 56.4x.

See valuation multiples for Syngene International and 12K+ public comps

Syngene International Financial Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $3.1B XXX $3.1B XXX XXX XXX
EV (current) $3.0B XXX $3.0B XXX XXX XXX
EV/Revenue 6.9x XXX 7.3x XXX XXX XXX
EV/EBITDA 24.6x XXX 22.6x XXX XXX XXX
EV/EBIT 41.9x XXX 41.0x XXX XXX XXX
EV/Gross Profit 9.3x XXX n/a XXX XXX XXX
P/E 56.4x XXX 52.7x XXX XXX XXX
EV/FCF 85.1x XXX 59.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Syngene International Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Syngene International Margins & Growth Rates

Syngene International's last 12 month revenue growth is 10%

Syngene International's revenue per employee in the last FY averaged $50K, while opex per employee averaged $28K for the same period.

Syngene International's rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Syngene International's rule of X is 53% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Syngene International and other 12K+ public comps

Syngene International Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth 10% XXX 12% XXX XXX XXX
EBITDA Margin 28% XXX 32% XXX XXX XXX
EBITDA Growth 6% XXX 4% XXX XXX XXX
Rule of 40 43% XXX 43% XXX XXX XXX
Bessemer Rule of X XXX XXX 53% XXX XXX XXX
Revenue per Employee XXX XXX $50K XXX XXX XXX
Opex per Employee XXX XXX $28K XXX XXX XXX
S&M Expenses to Revenue XXX XXX 1% XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX n/a XXX XXX XXX
Opex to Revenue XXX XXX 56% XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Syngene International Public Comps

See public comps and valuation multiples for Contract Research & Manufacturing and Laboratory Services comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Jubilant Pharmova XXX XXX XXX XXX XXX XXX
Biocon XXX XXX XXX XXX XXX XXX
Dishman Carbogen Amics XXX XXX XXX XXX XXX XXX
Cohance Lifesciences XXX XXX XXX XXX XXX XXX
Piramal Pharma XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Syngene International M&A and Investment Activity

Syngene International acquired  XXX companies to date.

Last acquisition by Syngene International was  XXXXXXXX, XXXXX XXXXX XXXXXX . Syngene International acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Syngene International

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Start Free Trial

About Syngene International

When was Syngene International founded? Syngene International was founded in 1993.
Where is Syngene International headquartered? Syngene International is headquartered in India.
How many employees does Syngene International have? As of today, Syngene International has 8.2K+ employees.
Who is the CEO of Syngene International? Syngene International's CEO is Mr. Jonathan Hunt.
Is Syngene International publicy listed? Yes, Syngene International is a public company listed on BOM.
What is the stock symbol of Syngene International? Syngene International trades under 539268 ticker.
When did Syngene International go public? Syngene International went public in 2015.
Who are competitors of Syngene International? Similar companies to Syngene International include e.g. Jubilant Pharmova, Biocon, Dishman Carbogen Amics, Cohance Lifesciences.
What is the current market cap of Syngene International? Syngene International's current market cap is $3.1B
What is the current revenue of Syngene International? Syngene International's last 12 months revenue is $436M.
What is the current revenue growth of Syngene International? Syngene International revenue growth (NTM/LTM) is 10%.
What is the current EV/Revenue multiple of Syngene International? Current revenue multiple of Syngene International is 6.9x.
Is Syngene International profitable? Yes, Syngene International is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Syngene International? Syngene International's last 12 months EBITDA is $121M.
What is Syngene International's EBITDA margin? Syngene International's last 12 months EBITDA margin is 28%.
What is the current EV/EBITDA multiple of Syngene International? Current EBITDA multiple of Syngene International is 24.6x.
What is the current FCF of Syngene International? Syngene International's last 12 months FCF is $35.1M.
What is Syngene International's FCF margin? Syngene International's last 12 months FCF margin is 8%.
What is the current EV/FCF multiple of Syngene International? Current FCF multiple of Syngene International is 85.1x.

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.